Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Lyell Immunopharma Trading Down 1.9 %
Shares of LYEL stock traded down $0.01 during trading on Friday, hitting $0.46. The company's stock had a trading volume of 491,707 shares, compared to its average volume of 1,042,424. The company has a market cap of $136.21 million, a PE ratio of -0.58 and a beta of -0.26. The business has a fifty day moving average of $0.53 and a 200-day moving average of $0.71. Lyell Immunopharma has a 52 week low of $0.39 and a 52 week high of $2.88.
Insider Transactions at Lyell Immunopharma
In other news, CFO Charles W. Newton acquired 200,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $0.56 per share, with a total value of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Lynn Seely acquired 175,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the purchase, the chief executive officer now directly owns 712,500 shares in the company, valued at $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 768,640 shares of company stock worth $449,508 in the last quarter. Insiders own 25.10% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.
View Our Latest Analysis on LYEL
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Stories

Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.